• Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (PubMed=8339266; PubMed=10071072; PubMed=10576511).
  
• Mutation; HGNC; 18318; ASXL1; Simple; p.Gly710Ter (c.2128G>T); Zygosity=Homozygous (PubMed=26623729).
  
• Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=7627932; PubMed=26623729).
  

PubMed=3332852; DOI=10.1016/S0950-3536(87)80037-9
Keating A.
Ph positive CML cell lines.
Baillieres Clin. Haematol. 1:1021-1029(1987)

PubMed=8339266
Beran M., Pisa P., O'Brien S., Kurzrock R., Siciliano M.J., Cork A., Andersson B.S., Kohli V., Kantarjian H.M.
Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase.
Cancer Res. 53:3603-3610(1993)

PubMed=7627932; DOI=10.1016/0165-4608(94)00282-g
Sen S., Zhou H.-Y., Andersson B.S., Cork A., Freireich E.J., Stass S.A.
p53 gene mutations with chromosome 17 abnormalities in chronic myelogenous leukemia blast crisis patients persist in long-term cell lines but may be acquired in acute myeloid leukemia cells in vitro.
Cancer Genet. Cytogenet. 82:35-40(1995)

PubMed=10071072; DOI=10.1016/S0145-2126(98)00171-4
Drexler H.G., MacLeod R.A.F., Uphoff C.C.
Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Leuk. Res. 23:207-215(1999)

PubMed=10576511; DOI=10.1016/S0145-2126(99)00131-9
Uphoff C.C., Habig S., Fombonne S., Matsuo Y., Drexler H.G.
ABL-BCR expression in BCR-ABL-positive human leukemia cell lines.
Leuk. Res. 23:1055-1060(1999)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=26623729; DOI=10.18632/oncotarget.6392; PMCID=PMC4792541
Valletta S., Dolatshad H., Bartenstein M., Yip B.H., Bello E., Gordon S., Yu Y.-T., Shaw J., Roy S., Scifo L., Schuh A., Pellagatti A., Fulga T.A., Verma A., Boultwood J.
ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts.
Oncotarget 6:44061-44071(2015)